Skip to main content
Sign In

Department of Psychiatry

Department of Psychology

Laura Martin, MD Assistant Professor 

           Laura Martin, MD

Bldg 500, Level 4-East

Phone:  303-724-6222

Email: Dr. Martin

 

Recent Publications

 

 

 

Laura F. Martin, MD

Associate Professor


ACADEMIC APPOINTMENTS, PROFESSIONAL POSITIONS, AND HONORS

Positions and Employment:

Community Medicine Internship, University of Colorado Denver (UCD), Denver, CO, 1997-1998                  

Psychiatry Residency, UCD, Denver, CO, 1998-2002                  

Attending, Colorado Mental Health Institute at Fort Logan, Denver, CO, 2000-2001 

Physician Investigator, Research and Development Service, Denver VAMC, Denver, CO, 2002-2008                  

Instructor, Department of Psychiatry, Division of Psychopharmacology, UCD, Aurora CO, 2002-2006                  

Assistant Professor, Department of Psychiatry, Division of Psychopharmacology, UCD, Aurora CO, 2006-2013  

Associate Training Director, Department of Psychiatry General Residency Program, UCD, Aurora CO, 2008-present  

Clinical Director, Behavioral Health and Wellness Program, Department of Psychiatry, UCD, Aurora CO, 2009-present 

Associate Professor, Department of Psychiatry, University of Colorado School of Medicine, Aurora CO, 2013-present

 

Other Experience and Professional Memberships:

Member, American Psychiatric Association

Secretary, Treasurer, Colorado Psychiatric Society

Member, National Alliance for the Mentally Ill

 

Honors:

Summer Research Fellowship, Wake Forest School of Medicine, 1994   

First Place, Medical Student Research Day, An Investigation of the Effect of Propofol on Hippocampal GABA-a Receptor Function Utilizing the Patch Clamp Technique, 1994   

Society of Biological Psychiatry Eli Lilly Travel Fellowship Award, 2002   

Distinguished Laughlin Fellow for professional achievement, dedication and scholarship in psychiatric residency, 2002   

American Psychiatric Association-Lilly Resident Research Award, 2003   

UCD Department of Psychiatry Junior Faculty Poster Session, Best Poster, 2004   

American Association of Chairs of Departments of Psychiatry Faculty Development Award in Psychopharmacology, 2005   

Steele Award for Excellence in Teaching (UCD Department of Psychiatry), 2006   

 

Teaching Activities:

Presentations:

Graduate Students: Lecture, “Schizophrenia, Bipolar Disorder and Measures of Inhibition,” Colorado State University Neurosciences Program, 2003; Lecture, “The Lowdown and Highlights of Bipolar Disorder,” 2004, 2006, 2008 NRSC 7614 - Neurobiological Basis of Neuropsychiatric Disorders, UC Denver

 

Psychiatry Residents: (PGYI) Course Director and Instructor, PGYI, Introduction to Scholarship, 2008 - present; (PGY II) Lecture, “Second Generation Antipsychotic Medications,” 2005; Lecture, “Structured Diagnostic Instruments in Research and Clinical Practice,” 2006-present; Lecture, “Rating Scales in Research and Clinical Practice,” 2006-present; Lecture, “Selective Serotonin Reuptake Inhibitors,” 2006Lecture, “Dual Mechanism Antidepressants,” 2006; Lecture, “Antipsychotic Associated Weight Gain,” 2007; Lecture, “The Role of NeuroImaging in Research,” 2008-present; (PGYIII) Course Director and Instructor, PGYIII Tobacco Cessation, 2008-present; (PGYIV) Course Co-Director and Primary Instructor, PGYIV Psychiatry Advanced Psychopharmacology, 2004-present

 

Attending Duties:

Medical Student: (MS3) Inpatient Psychiatric Rotations, 1998-99; Consultation Liason Service, 1999-2000, 2008-present

 

Psychiatry Resident: (PGYI) Inpatient Psychiatric Services and Call, 2001-2005; (PGYII)  Inpatient Psychiatric Services and Call, 2001-2005; Off ward Supervision, 2000-01, 2002-04; Consultation Liason Service, 2008-present; (PGYIII) Consultation Liason and Emergency Room Call, 2001-2005

 

Research Trainees: Neurosciences Graduate Student First Year Rotation, 2004; MS1  Scholarly Projects, 2007-present (3 students); Resident  Research Track Experiences, 2006 – present (2 residents)

 Administrative Duties:

Course Director and Instructor, PGYI, Introduction to Scholarship, 2008 - present

Course Co-Director and Primary Instructor, PGYIV Psychiatry Advanced Psychopharmacology, 2004-present

Course Director and Instructor, PGYIII Tobacco Cessation, 2008-present

Associate Residency Training Director, Department of Psychiatry, 09/2008 – present

 

Clinical Activities:

Attending Physician, State Mental Health Institute at Fort Logan, 2000-2001

Attending Physician, University of Colorado Hospital Inpatient Service, 07/2002-2008

Outpatient practice, University Physician’s Inc, 2004-present

Attending, University of Colorado Hospital Psychiatry Consultation-Liason Service, 01/2009-present

Clinical Director, Behavioral Health and Wellness Center, 01/2009-present

 

SCHOLARSHIPS AND PUBLICATIONS

Selected Peer-Reviewed Publications:

Martin LF, Kem WR and FreedmanR (2004).  Alpha-7 Nicotinic Receptor Agonists:  Potential New Candidates for the Treatment of Schizophrenia.  Psychopharmacology 174: 54-64.

 

Harris JG, Kongs S, Allensworth D, Martin LF, Tregellas J, Sullivan B, Zerbe G and Freedman R (2004).  Effects of Nicotine on Cognitive Deficits in Schizophrenia.  Neuropsychopharmacology 29: 1378-1385.

 

Olincy A and Martin L (2005). Failure to inhibit the P50 auditory evoked potential in bipolar subjects with a history of psychosis.  American Journal of Psychiatry 162 (1): 43-9.

 

Tregellas J, Tanabe JL, Martin LF and Freedman R (2005).  fMRI of Response to Nicotine During a Smooth Pursuit Eye Movement Task in Schizophrenia.  American Journal of Psychiatry 162 (2):  391-393.

 

Freedman R, Ross RG, Leonard S, Worsley M, Adams C, Waldo M, Tregellas J, Martin L, Olincy A, Tanabe J, Kisley M, Hunter S and Stevens K (2005).  Early Biomarkers of Psychosis.  Dialogues in Clinical Neuroscience 7(1):  17-29.

 

Tanabe J, Tregellas JR, Martin LF, Freedman R (2005).  Effects of nicotine on hippocampal and cingulate activity during smooth pursuit eye movement in schizophrenia. Biological Psychiatry 59 (8): 754-761.

 

Ann Olincy; Josette G. Harris; Lynn L. Johnson; Vicki Pender; Susan Kongs; Diana Allensworth; Jamey Ellis; Gary O. Zerbe; Sherry Leonard; Karen E. Stevens; James O. Stevens; Laura Martin; Lawrence E. Adler; Ferenc Soti; William R. Kem; Robert Freedman (2006). Proof-of-Concept Trial of an 7 Nicotinic Agonist in Schizophrenia.  Archives of General Psychiatry  63:  630-638.

 

Martin LF, Hall MH, Leonard S, Olincy A, Tregellas J, Freedman R (2007.) Sensory Gating and Alpha-7 Nicotinic Receptor Gene Allelic Variants in Schizoaffective Disorder, Bipolar Type.  American Journal of Medical Genetics 144B: 611-14.

 

Martin LF, Olincy A, Hall MH, Ross R, Zerbe GO and Freedman R. (2007)  The Neurophysiology of  Schizophrenia, Bipolar Disorder and Schizoaffective Disorder.   American Journal of Psychiatry 164 (12):  1900-6.

Tregellas JR, Shatti S, Tanabe JL, Martin LF, Gibson L, Wylie K, Freedman R, Rojas DC. (2007) Gray Matter Volume Differences and the Effects of Smoking on Gray Matter in Schizophrenia.  Schizophrenia Research 97(1-3): 242-9. 

Freedman R, Olincy A, Buchanan RW, Harris JG, Gold JM, Johnson L, Allensworth D, Guzman A, Clement B, Ball MP, Kutnick J, Pender V, Martin LF, Stevens KE, Wagner BD, Zerbe GO, Soti F and Kem WR.  (2007) Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia Am J Psychiatry. 2008; 165:1040-1047

 

Martin LF, Davalos DB and Kisley MA.  The effects of nicotine on temporal processing as measured by the mismatch negativity waveform Nicotine & Tobacco Research, Volume 11, Number 6 (June 2009) 698–706.

 

Tegellas JR, Olincy A, Johnson L, Tanabe J, Shatti S, Martin LF, Singel D, Du Y, Soti F, Kem WR, Freedman R.  Functional Magnetic Resonance Imaging of Effects of a Nicotinic Agonist in Schizophrenia.  Neuropsychopharmacology (accepted 11/2009)

 

Grants and Contracts:

Research Career Development Award from the Department of Veterans Affairs for the nearly full time pursuit of medical research training funding full salary together with $20,000 annually for research, 1/8/06 to 1/7/09

 

Pfizer (Morris) “A Phase 3b 12-week, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of varenicline tartrate (CP-526,555) 1mg BID for smoking cessation in subjects with schizophrenia and schizoaffective disorder, 01/09 – 12/09

 

Smoking Cessation and Clinical Symptoms in Schizophrenia; Principal Investigator;  National Association for Research on Schizophrenia and Depression (NARSAD) Young Investigator Award; 07/2009-06/2011; 20% effort; $60,000